1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Juvenile Rheumatoid Arthritis Global Clinical Trials Review, H2, 2016

Juvenile Rheumatoid Arthritis Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Juvenile Rheumatoid Arthritis Global Clinical Trials Review, H2, 2016" provides an overview of Juvenile Rheumatoid Arthritis clinical trials scenario. This report provides top line data relating to the clinical trials on Juvenile Rheumatoid Arthritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Juvenile Rheumatoid Arthritis Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Juvenile Rheumatoid Arthritis to Immunology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Juvenile Rheumatoid Arthritis to Immunology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials 28
Prominent Drugs 30
Clinical Trial Profile Snapshots 31
Appendix 88
Abbreviations 88
Definitions 88
Research Methodology 89
Secondary Research 89
About GlobalData 90
Contact Us 90
Disclaimer 90
Source 91

List of Tables
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Region, 2016* 6
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14
Proportion of Juvenile Rheumatoid Arthritis to Immunology Clinical Trials, G7 Countries (%), 2016* 15
Juvenile Rheumatoid Arthritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Juvenile Rheumatoid Arthritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Juvenile Rheumatoid Arthritis to Immunology Clinical Trials, E7 Countries (%), 2016* 18
Juvenile Rheumatoid Arthritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Juvenile Rheumatoid Arthritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Juvenile Rheumatoid Arthritis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List of Figures
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
Proportion of Juvenile Rheumatoid Arthritis to Immunology Clinical Trials, G7 Countries (%), 2016* 15
Juvenile Rheumatoid Arthritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Juvenile Rheumatoid Arthritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Juvenile Rheumatoid Arthritis to Immunology Clinical Trials, E7 Countries (%), 2016* 18
Juvenile Rheumatoid Arthritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Juvenile Rheumatoid Arthritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Juvenile Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Juvenile Rheumatoid Arthritis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Juvenile Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
GlobalData Methodology 89

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Rheumatoid Arthritis in 17 Major Markets Rheumatoid arthritis (RA) is classified as an autoimmune disease and occurs when the immune ...

Epiomic Epidemiology Series: Lower Back Pain and Sciatica Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Lower Back Pain and Sciatica Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lower Back Pain and Sciatica in 9 Major Markets Low back pain (LBP) is defined as experiencing musculoskeletal pain, muscle tension, ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.